secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sagimet Biosciences Inc. (SGMT)
CIK:        0001400118
Form:       8-K
Filed at:   2024-03-25T23:59:59+00:00
Accession:  0001104659-24-038101
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sagimet FY2023 net loss $27.9M; denifanstat Phase 2b hits endpoints; board adds Walbert, Hoelscher
--------------------------------------------------------------------------------

- Net loss $27.9M for FY2023 vs $30.5M in 2022; revenue $2.0M from milestone payment.
- Cash, equivalents and securities $94.9M at Dec 31, 2023; Jan 2024 offering added $104.7M net.
- Denifanstat Phase 2b FASCINATE-2 met primary endpoints: MASH resolution 36% vs 13% (p=0.0022); fibrosis improvement 41% vs 18% (p=0.005).
- Board expanded from 7 to 9 directors; Tim Walbert (ex-Horizon CEO) and Paul Hoelscher (ex-Horizon CFO) appointed eff. April 1, 2024.
- Directors Richard Rodgers and Jinzi Wu will not stand for re-election at June 2024 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1400118/000110465924038101/0001104659-24-038101-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1400118/000110465924038101/tm249600d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-038101

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer